Engineered immune cells take on tough lymphoma
NCT ID NCT07508605
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a new type of cell therapy called CD19/CD20 CAR/TRuC-T for people with B-cell lymphoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize and attack cancer cells. The trial will enroll 20 adults and primarily check for safety, while also looking at whether the treatment can shrink tumors.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CD19/CD20 CAR/TRuC-T cells (a type of immune cell therapy)
- What this could lead to
- If it works, this could offer a new treatment option for patients whose lymphoma has not responded to other therapies.
- What could go wrong
- This is a very early (Phase 1/2) and small trial with only 20 participants. The therapy may cause serious side effects, and it is not yet known if it will effectively control the cancer long-term.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shenzhen University General Hospital
RECRUITINGShenzhen, Guangdong, 518055, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could an AI-Designed pill take on Hard-to-Treat cancers?
- Engineered immune cells take aim at tough childhood cancers
- Experimental 'Off-the-Shelf' CAR-T therapy takes on tough lymphoma
- Promising CAR-T trial for blood cancer withdrawn before starting
- Nanobody-Powered CAR-Ts take on tough lymphoma
- New hope for tough lymphomas: experimental drug STP938 enters human trials